CAR-T疗法就是嵌合抗原受体T细胞免疫疗法，英文全称Chimeric Antigen Receptor T-Cell Immunotherapy。这是一种治疗肿瘤的新型精准靶向疗法，近几年通过优化改良在临床肿瘤治疗上取得很好的效果，是一种非常有前景的，能够精准、快速、高效，且有可能治愈癌症的新型肿瘤免疫治疗方法。T细胞也叫T淋巴细胞，是人体白细胞的一...
[5]https://www.clinicaltrialsarena.com/news/cellectis-car-t-cell-therapies-2023/?cf-view [6]https://lymphomahub.com/medical-information/dual-targeted-car-t-cell-therapy-key-updates-from-tct-2023 [7]https://www.glpg.com/press-releases/galapagos-presents-new-encouraging-data-at-ash-2023-fro...
所谓CAR-T疗法,全称是嵌合抗原受体T细胞疗法(Chimeric Antigen Receptor T cell therapy),是细胞治疗的一种。 其实大家对细胞治疗并不陌生,如输注患者本人或家属或健康脐带血的CIK细胞、DC-CIK细胞等。CIK细胞是细胞因子诱导的杀伤细胞(Cytokine-Induced Killer cells),DC-CIK...
[1]https://koreajoongangdaily.joins.com/news/2023-10-12/business/industry/PeproMene-Bio-reports-positive-phase-1-results-for-CART-therapy/1888772 [2]https://www.cancer.gov/about-cancer/treatment/research/car-t-cells [3]Tomasik J,et al.Next generations of CAR-T cells - new therapeutic opp...
Phases and challenges of treatment with autologous CAR T cells in autoimmune diseases CD19 CART细胞于2021年首次用于治疗一名患有严重难治SLE的20岁女性,结果显示,给自身免疫疾病的患者制备CART细胞是可行的,同时,患者对CART细胞输注具有良好的耐受性,且没有导致任何严重的毒性作用...
Phases and challenges of treatment with autologous CAR T cells in autoimmune diseases CD19 CART细胞于2021年首次用于治疗一名患有严重难治SLE的20岁女性,结果显示,给自身免疫疾病的患者制备CART细胞是可行的,同时,患者对CART细胞输注具有良好的耐受性,且没有导致任何严重的毒性作用。这种治疗方法致使体内B细胞快速...
CART治疗淋巴瘤,120万天价的CAR-T真能成为晚期淋巴瘤的救命稻草吗 据澎湃新闻报道，2021年一则“120万一针的天价抗癌产品——CAR-T，两个月清零癌细胞”的新闻引爆网络。据悉，接受CAR-T治疗的陈女士是一位“弥漫性大B细胞淋巴瘤”患者，因其存在TP53基因突变，经传统的一二线治疗效果不佳，遂在各项临床试验条件...
[6]https://lymphomahub.com/medical-information/dual-targeted-car-t-cell-therapy-key-updates-from-tct-2023 [7]https://www.glpg.com/press-releases/galapagos-presents-new-encouraging-data-at-ash-2023-from-ongoing-cd19-car-t-studies-with-glpg5201-and-glpg5101/ ...
[1]Daei Sorkhabi A,et al.The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges,and counterstrategies. Front Immunol.2023 Mar 20;14:1113882.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067596/ [2]Li H,et al.CAR-T cells for Colorectal ...
Collectively, issues originating in tumor cells, T cells, and the TME present significant hurdles to long-term remission after CART cell therapy. Various strategies to combat CART cell resistance have shown promise in preclinical studies and early clinical trials and are crucial to achieving durable ...